S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

CVM Cel Sci Corporation New

0.702451

-0.01755 (-2.44%)

Last Updated: 06:25:15

Delayed by 15 minutes

Form S-3 - Registration statement under Securities Act of 1933

nullnullnullnullnull

Cel Sci (AMEX:CVM)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Cel Sci Charts.

Cel Sci (AMEX:CVM)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Cel Sci Charts.

Cel Sci Corporation New News

Form EFFECT - Notice of Effectiveness
Friday 8 November 2024 (5 days ago) • Edgar (US Regulatory)

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Friday 8 November 2024 (5 days ago) • Business Wire

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
Thursday 31 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Saturday 26 October 2024 (3 weeks ago) • Edgar (US Regulatory)

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
Wednesday 23 October 2024 (3 weeks ago) • Business Wire

Form AW - Amendment Withdrawal Request
Friday 11 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (1 month ago) • Edgar (US Regulatory)

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Tuesday 1 October 2024 (1 month ago) • Business Wire

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
Monday 16 September 2024 (2 months ago) • Business Wire

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
Tuesday 10 September 2024 (2 months ago) • Business Wire

More Cel Sci Corporation New News Articles

The Travelers Companies

SEKG25 - Fevereiro 2025

Running Fox Resource

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions